AbbVie is a research-based biopharmaceutical company. The company's products are focused on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus and human immunodeficiency virus; neurological disorders, such as Parkinson's disease; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis; pain associated with endometriosis; as well as other serious health conditions. The company also has medicines in clinical development across immunology, oncology and neuroscience, with additional targeted investment in cystic fibrosis and women's health.
Acadia Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of medicines focusing on central nervous system disorders. The company has a portfolio of product including its drug, NUPLAZID (pimavanserin), which has been approved by the U.S. Food and Drug Administration for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PD Psychosis). NUPLAZID is a selective serotonin inverse agonist preferentially targeting 5-HT2A receptors with no appreciable affinity for dopaminergic, histaminergic, or muscarinic receptors.
Agios Pharmaceuticals is a biopharmaceutical company focused on areas of hematologic malignancies, solid tumors and rare genetic diseases. The company's product, TIBSOVO? (ivosidenib) is for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (R/R AML) with a susceptible isocitrate dehydrogenase (IDH) 1 mutation. The company's other product is IDHIFA? (enasidenib) for patients with R/R AML and an IDH2 mutation. The company's pre-commercial clinical cancer product candidates include: vorasidenib, a brain-penetrant pan-IDH mutant inhibitor; and AG-270, an orally available selective inhibitor of methionine adenosyltransferase 2a.
Eli Lilly and Company discovers, develops, manufactures, and markets products in a single business segment: human pharmaceutical products. The company's human pharmaceutical products include: diabetes and other endocrinology products, immunology products, neuroscience products, oncology products, and other products. The company's diabetes and other endocrinology products include: Baqsimi? and Basaglar?. The company's immunology products include: Olumiant? and Taltz?. The company's neuroscience products include: Cymbalta? and Emgality?. The company's oncology products include: Alimta?, Cyramza?, Erbitux? and Verzenio?. The company's other products include: Cialis?.
Fulgent Genetics is a holding company. Through its subsidiaries, the company is a technology company providing genetic testing and providing physicians with diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that allows it to provide test menu. The company performs full-gene sequencing with deletion/duplication analysis in single-gene tests; pre-established, multi-gene, disease-specific panels; and customized panels to meet customer needs. The company's test menu includes single-gene tests and panels that test for genetic conditions, including various cancers, cardiovascular diseases, neurological disorders and pediatric conditions.
Laboratory Corporation of America Holdings is a life sciences company that is focused on guiding patient care. The company reports its business in the following segments: LabCorp Diagnostics (LCD) and Covance Drug Development (CDD). LCD is an independent clinical laboratory business. LCD provides a menu of requested and specialty testing through a network of primary and specialty laboratories across the United States. CDD provides drug development, medical device and diagnostic development solutions from early-stage research to clinical development and commercial market access. CDD engages in early development and clinical trials in each therapeutic category.
Luminex develops, manufactures and sells biological testing technologies and products with applications in the life sciences industries, including diagnostics, pharmaceutical and research. The company delivers its products to various market segments, including multiplexing, reduction of labor and ability to test for proteins and nucleic acids. The company's products include: instruments, which include Luminex? 100/200?, FLEXMAP? 3D, MAGPIX?, ARIES?, and ARIES? M1; consumables, which include MicroPlex? Microspheres, MagPlex? Microspheres, and xTAG? Microspheres; software, which includes xPONENT?, TDAS?, SYNCT?, and IDEAS?; and clinical diagnostic assay product families, which include ARIES? Cassettes.
PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. The company has the following products, Translarna? (ataluren) and Emflaza? (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. The company's gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC) deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
Quidel is engaged in the development, manufacturing and marketing of diagnostic testing solutions. The company provides diagnostic testing solutions under various brand names, including, among others, the following: Quidel?, QuickVue?, QuickVue+?, Sofia?, Triage?, AmpliVue?, Solana?, Virena?, MicroVue?, Lyra?, FreshCells?, D3?, FastPoint?, ReadyCells?, Super E-Mix?, InflammaDry?, AdenoPlus?, ELVIRA?, ELVIS? and Thyretain?. The company's diagnostic testing solutions are separated into its four product categories: rapid immunoassay, cardiac immunoassay, specialized diagnostic solutions and molecular diagnostic solutions.
Repligen is a life sciences company that develops and commercializes bioprocessing technologies and systems used in the process of manufacturing biological drugs. The company's bioprocessing business is comprised of: Chromatography, which includes products used in downstream purification, development, manufacturing and quality control of biological drugs; Filtration, which includes XCell Alternating Tangential Flow systems that are used in upstream perfusion cell culture processing; Process Analytics, which complements and supports its Filtration, Chromatography and Proteins franchises; and OEM products, which are represented by its Protein A affinity ligands and cell culture growth factor products
Vertex Pharmaceuticals is focused on developing and commercializing therapies for the treatment of cystic fibrosis (CF) and developing research and development programs in other indications. The company's marketed products are TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor), which are approved to treat patients with CF who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. The company is evaluating CTX001, a genetic therapy as a potential treatment for sickle cell disease and beta-thalassemia.
Vermilion Research delivers timely, actionable, and unique research inputs to professional investors. Our research strategists highlight securities which we believe are at major inflection points, based on our various proprietary technical indicators, and offer asymmetric risk/return profiles. We believe our research methodology, which is not limited by industry sector or market capitalization, enables us to deliver superior investment recommendations.
Our process begins by organizing all actively traded stocks into coherent sectors, then into logical industry groups. We then apply our proprietary relative strength tools to identify developing price trends. Once attractive trends are identified within a selected sectors or groups, we screen for individual stocks which we believe offer the best risk/reward profile. Vermilion offers U.S. and global equity market research products. Vermilion’s research team, which has received numerous awards and accolades, has a combined 70 year of experience in the analysis of investment securities.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.